Please assess the completion status of the following clinical trial:

Trial Title: Targeting ER Stress in Vascular Dysfunction

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: DOUBLE
- Phase: EARLY_PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Young, healthy weight adults (age: 18-35; BMI 18.5-24.9 kg/m2)~* Young, obese adults (age: 18-35; BMI 30- 39.9 kg/m2)~* Older, healthy weight adults (age: 60-80; 18.5-24.9 kg/m2)~* Older, obese adults (age: 60-80; 30-39.9 kg/m2)~Exclusion Criteria:~* blood pressure \>140/90 mmHg~* triglycerides \>500 mg/dL or LDL cholesterol \>190 mg/dL~* current smoking or history of smoking in the last 12 months~* diagnosed chronic disease including cancer, cardiovascular, diabetes, kidney, liver, and pancreatic disease~* weight change \>3 kg in the past 3 months or actively trying to lose weight~* \>12 alcoholic drinks/week~* hormone replacement therapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: t

Study Arms:
- TUDCA (Type: EXPERIMENTAL): Young and older healthy weight and obese participants will visit the lab for assessment of vascular function prior to the intervention. Aortic stiffness will be evaluated non-invasively using carotid-femoral pulse-wave velocity. A physician will place a catheter in the brachial artery for endothelial cell biopsies and local vasodilator infusions. A venous catheter will also be placed for the systemic ascorbic acid infusion. Aortic stiffness measures and vascular responses to vasodilator infusions will be performed before and after the ascorbic acid infusion. Following the completion of the vascular assessments, participants will receive 1750 mg/day of the dietary supplement tauroursodeoxycholic acid (TUDCA) for 8 weeks. Participants will return to the lab after the 8 week intervention and the vascular assessments described above will be repeated.
- Placebo (Type: PLACEBO_COMPARATOR): Older obese participants will visit the lab for assessment of vascular function prior to the intervention. Aortic stiffness will be evaluated non-invasively using carotid-femoral pulse-wave velocity. A physician will place a catheter in the brachial artery for endothelial cell biopsies and local vasodilator infusions. A venous catheter will also be placed for the systemic ascorbic acid infusion. Aortic stiffness measures and vascular responses to vasodilator infusions will be performed before and after the ascorbic acid infusion. Following the completion of the vascular assessments, participants will receive oral capsules containing a placebo treatment for 8 weeks. Participants will return to the lab after the 8 week intervention and the vascular assessments described above will be repeated.

Based on this trial design, predict the completion outcome and termination type (if applicable).